VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration

Expert Opinion on Investigational Drugs

Volumn 18, Issue 10, 2009, Pages 1573-1580

  Dixon, James A ^a   Oliver, Scott C N ^a   Olson, Jeffrey L ^a   Mandava, Naresh ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Aflibercept; AMD; Angiogenesis; Neovascularization; VEGF; VEGF inhibition; VEGF trap

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BEVASIRANIB; GROWTH FACTOR; MECAMYLAMINE; PAZOPANIB; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; SMALL INTERFERING RNA; TG 100801; UNCLASSIFIED DRUG; VASCULOTROPIN A; VATALANIB;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; DIABETIC MACULAR EDEMA; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; EYE INFLAMMATION; EYE PAIN; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; LOW DRUG DOSE; NONHUMAN; PROTEINURIA; REFRACTION ERROR; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VISUAL IMPAIRMENT; VITREOUS BODY DETACHMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; BLINDNESS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; MACULAR DEGENERATION; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349330817     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903201684     Document Type: Review

References (59)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122(4):564-572 (Pubitemid 38456293)
2. Magnitude and causes of visual impairment [fact sheet no. 282]. Available from: http://www.who.int/mediacentre/factsheets/fs282/en/ [Accessed 1 Sep 2008]
3. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122(4):477-485 (Pubitemid 38456282)
4. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1986;104(5):694-701 • A seminal paper in its era, regarding the use of laser photocoagulation for neovascular AMD.
5. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1990;108(6):816-824
6. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109(9):1242-1257
7. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109(9):1232-1241
8. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109(9):1220-1231
9. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1993;111(9):1200-1209
10. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1994;112(4):500-509
11. Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol 1996;114(4):400-412
12. Fine SL, Hawkins B, Maguire M. Macular photocoagulation study. Arch Ophthalmol 1984;102(11):1583
13. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113(6):992-1001, e1006 • The first anti-VEGF agent proven to be effective for neovascular AMD was pegaptanib.
14. Kaiser PK. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 2006;244(9):1132-1142 (Pubitemid 44269592)
15. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2007;(3):CD002030 (Pubitemid 351805609)
16. Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand 2006;84(3):282-288 (Pubitemid 43756617)
17. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995;1(2):182-193
18. Vinores SA, Xiao WH, Aslam S, et al. Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 2006;206(3):749-758 (Pubitemid 43191050)
19. Zhou J, Pham L, Zhang N, et al. Neutrophils promote experimental choroidal neovascularization. Mol Vis 2005;11:414-424 (Pubitemid 41410238)
20. Ishibashi T, Hata Y, Yoshikawa H, et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997;235(3):159-167 (Pubitemid 27129479)
21. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120(3):338-346
22. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996;122(3):393-403 (Pubitemid 26300056)
23. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81(2):154-162 (Pubitemid 27092496)
24. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37(9):1929-1934 (Pubitemid 26324159)
25. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113(11):2002 e2001-12 • Data from this publication heralded the advent of the bevacizumab versus ranibizumab era for treatment of neovascular AMD.
26. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-1431 •• The MARINA study was a pivotal trial leading to the approval of ranibizumab for neovascular AMD.
27. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432- 1444 •• The ANCHOR study was pivotal in obtaining the FDA approval of ranibizumab for neovascular AMD. (Pubitemid 44511558)
28. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65, e55
29. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143(4):566-583 • Variable dosing of ranibizumab for neovascular AMD is now the norm in many practices; this was the first large retrospective of a variable approach.
30. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145(2):239-248
31. Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009;29(3):313-318
32. Moreno SF, Paloma JB. Therapeutic anti-VEGF in age-related macular degeneration: ranibizumab and bevacizumab controversy. Br J Ophthalmol 2008;92(6):866-867 (Pubitemid 351839593)
33. Safety and Efficacy of Oral PTK787 in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) [ClinicalTrials.gov identifier: NCT00138632] ClinicalTrials.gov [online]. Available from: http//clinicaltrials.gov/ct2/show/ NCT00138632 [Accessed 19 Sep 2008]
34. A study to evaluate to safety, tolerability and PK of pazopanib eye drops in healthy adult and elderly subjects. [ClinicalTrials. gov identifier: NCT00733304] ClinicalTrials.gov [online]. Available from: http//clinicaltrials. gov/ct2/show/NCT00733304 [Accessed 19 Sep 2008]
35. Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD [ClinicalTrials.gov identifier: NCT00509548] ClinicalTrials.gov [online]. Available from: http//clinicaltrials.gov/ct2/show/ NCT00509548 [Accessed 19 Sep 2008]
36. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON) [ClinicalTrials.gov identifier: NCT00557791] ClinicalTrials.gov [online]. Available from: http//clinicaltrials. gov/ct2/show/ NCT00557791 [Accessed 19 Sep 2008]
37. Study of AdGVPEDF.11D in Neovascular Age-Related Macular Degeneration (AMD) [ClinicalTrials.gov identifier: NCT00109499] ClinicalTrials.gov [online]. Available from: http//clinicaltrials.gov/ct2/show/NCT00109499 [Accessed 19 Sep 2008]
38. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46(2):726-733 (Pubitemid 40270359)
39. Rudge JS, Holash J, Hylton D, et al. Inaugural article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 2007;104(47):18363-18370 (Pubitemid 350210713)
40. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113(9):1522 e1521-14 (Pubitemid 44292331)
41. Hariprasad S. Fluorescein angiographic and OCT outcomes of a phase I, dose-escalation, safety, tolerability and bioactivity study of intravitreal VEGF Trap in patients with neovascular AMD: The CLEAR-IT 1 Study. Paper presented at: Combined Meeting of the Club Jules Gonin and the Retina Society; Oct 15-20th, 2006; Cape Town, South Africa
42. Nguyen Q, Hariprasad S, Browning D, et al. Interim results of a phase I, dose-escalation, safety, tolerability, and bioactivity study of intravitreal VEGF Trap in patients with neovascular AMD: The CLEAR-IT 1 Study [abstract no. E-2868]. Paper presented at: Combined Meeting of the Club Jules Gonin and the Retina Society; Oct 15-20th, 2006; Cape Town, South Africa
43. Nguyen Q, for the CLEAR-IT 1 investigators. A randomized comparison of the safety, tolerability, and bioactivity study two dose levels of intravitreal VEGF trap in patients with neovascular age-related macular degeneration. Paper presented at: Retina Society Annual Scientific Meeting; Sep 27-30th, 2007; Boston, MA
44. Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol 2009;93(2):144-149
45. VEGF Trap-Eye in Wet AMD. CLEAR-IT 2: Summary of One-Year Key Results. Paper presented at: Retinal Society Annual Scientific Meeting; Sep 28th, 2008; Scottsdale, AZ
46. Double-Masked Study of Efficacy and Safety of IVT VEGF Trap-Eye in Subjects With Wet AMD (VIEW 1) [ClinicalTrials.gov identifier: NCT00509795] ClinicalTrials.gov [online]. Available from: http//clinicaltrials.gov/ct2/show/ NCT00509795 [Accessed 28 Sep 2008]
47. VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW 2). [ClinicalTrials.gov identifier: NCT00637377] ClinicalTrials.gov [online]. Available from: http//clinicaltrials.gov/ct2/show/NCT00637377 [Accessed 28 Sep 2008]
48. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113(6):1020-1027 (Pubitemid 43795240)
49. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125(3):309-317 (Pubitemid 46425557)
50. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or irvine-gass syndrome.Am J Ophthalmol 2009;147(6):1048-54, 1054.e1-2
51. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006;103(10):3896-3901 (Pubitemid 43376652)
52. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185 (Pubitemid 46829388)
53. Gragoudas ES, Adamis AP, Cunningham ET, et al.; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816
54. Heier JS, Boyer DS, Ciulla TA, et al.; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006;124:1532-1542
55. Kaiser PK; Registry of Visudyne AMD Therapy Writing Committee, Boyer DS, Garcia R, Hao Y, et al. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009;116(4):747-755
56. Efficacy/safety of verteporfin photodynamic therapy and ranibizumab compared with ranibizumab in patients with subfoveal choroidal neovascularization. [ClinicalTrials.gov identifier: NCT00436553] ClinicalTrials.gov [online]. Available from: http//clinicaltrials.gov/ct2/show/ NCT00436553 [Accessed 28 Sep 2008]
57. Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) [ClinicalTrials.gov identifier: NCT00492284] ClinicalTrials.gov [online]. Available from: http//clinicaltrials.gov/ct2/show/ NCT00492284 [Accessed 28 Sep 2008]
58. Avila MP, Farah ME, Santos A, et al. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol 2009;93(3):305-309
59. Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration (CABERNET) [ClinicalTrials.gov identifier: NCT00454389] ClinicalTrials.gov [online]. Available from: http://clinicaltrials.gov/ct2/show/ study/NCT00454389?term=cabernet&rank=1&show-locs=Y [Accessed 28 May 2009]